Order Article Reprints

Basso U, Paolieri F, Rizzo M, De Giorgi U, Bracarda S, Antonuzzo L, Atzori F, Cartenì G, Procopio G, Fratino L, et al. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. Cancers. 2022; 14(9):2293. https://doi.org/10.3390/cancers14092293

Basso, Umberto, Federico Paolieri, Mimma Rizzo, Ugo De Giorgi, Sergio Bracarda, Lorenzo Antonuzzo, Francesco Atzori, Giacomo Cartenì, Giuseppe Procopio, Lucia Fratino, and et al. 2022. "Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study" Cancers 14, no. 9: 2293. https://doi.org/10.3390/cancers14092293

Basso, U., Paolieri, F., Rizzo, M., De Giorgi, U., Bracarda, S., Antonuzzo, L., Atzori, F., Cartenì, G., Procopio, G., Fratino, L., D’Arcangelo, M., Fornarini, G., Zucali, P., Cusmai, A., Santoni, M., Pipitone, S., Carella, C., Panni, S., Deppieri, F. M., ... Tortora, G. (2022). Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. Cancers, 14(9), 2293. https://doi.org/10.3390/cancers14092293